This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comparative Study

. 2004 Feb 28;363(9410):735-6; author reply 736.

doi: 10.1016/S0140-6736(04)15678-X.

Ximelagatran or warfarin in atrial fibrillation?

Raymond MacAllister, Aroon D Hingorani, Juan P Casas

PMID: 15001337
DOI: 10.1016/S0140-6736(04)15678-X

Comparative Study

Ximelagatran or warfarin in atrial fibrillation?

Raymond MacAllister et al. Lancet. 2004.

. 2004 Feb 28;363(9410):735-6; author reply 736.

doi: 10.1016/S0140-6736(04)15678-X.

Authors

Raymond MacAllister, Aroon D Hingorani, Juan P Casas

PMID: 15001337
DOI: 10.1016/S0140-6736(04)15678-X

No abstract available

PubMed Disclaimer

Comment on

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Olsson SB, et al. Lancet. 2003 Nov 22;362(9397):1691-8. doi: 10.1016/s0140-6736(03)14841-6. Lancet. 2003. PMID: 14643116 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information